sábado, 1 de junio de 2024
Psychoactive Drugs Are Having a Moment. The FDA Will Soon Weigh In. By Dawn Megli MAY 29, 2024
https://kffhealthnews.org/news/article/psychoactive-drugs-popularity-fda-regulation-studies-mdma/?utm_campaign=KHN%20-%20Weekly%20Edition&utm_medium=email&_hsenc=p2ANqtz--KaN8mcknk9_8dw2iVwInPR9AZjK3kvdw5RUpQOiXNNzTS3Sypng86Ux2qqF_tZsK8plsoRKg1Yw9-NdRWBoz1Hc3UeQ&_hsmi=309622936&utm_content=309622936&utm_source=hs_email
Psychoactive Drugs Are Having a Moment. The FDA Will Soon Weigh In.
By Dawn Megli
Mounting evidence suggests psychoactive drugs including LSD, ketamine, mushrooms, and MDMA can be powerful treatments for severe depression and PTSD. But not everyone is convinced. And even if such drugs gain FDA approval, safety protocols could render them extremely expensive.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario